已收盤 09-20 16:00:00 美东时间
-0.730
-1.35%
Cantor Fitzgerald analyst Josh Schimmer reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and maintains $90 price target.
09-16 23:36
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq ...
08-13 04:05
Crinetics Pharmaceuticals : Oppenheimer Cuts Target Price to $73 From $74
08-09 19:52
Crinetics Pharmaceuticals - Marc Wilson Will Be Transitioning From His Role as ...
08-09 04:46
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.85) by 10.59 percent. This is unchanged from the same period last year. The
08-09 04:39
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Resultsan...
08-09 04:05
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants UnderNasd...
07-11 07:29
Crinetics Pharmaceuticals Inc : JP Morgan Raises Target Price to $54 From $47
07-09 12:20
6月30日,礼来与Radionetics达成合作,引进其小分子G蛋白偶联受体(GPCR)靶向放射性药物技术。根据协议条款,Radionetics将收到1.4亿美...
07-03 10:13
Throughout the last three months, 11 analysts have evaluated Crinetics Pharmace...
06-29 01:01